Orforglipron + Insulin Glargine
Phase 3ActiveInterest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Trial Timeline
Apr 3, 2023 → Mar 1, 2026
NCT ID
NCT05803421About Orforglipron + Insulin Glargine
Orforglipron + Insulin Glargine is a phase 3 stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is active. This product is registered under clinical trial identifier NCT05803421. Target conditions include Type 2 Diabetes, Obesity, Overweight or Obesity.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05803421 | Phase 3 | Active |
Competing Products
20 competing products in Type 2 Diabetes